Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease

Yaroslau Compta, María J. Martí, Naroa Ibarretxe-Bilbao, Carme Junqué, Francesc Valldeoriola, Esteban Muñoz, Mario Ezquerra, Jose Ríos, Eduardo Tolosa

Research output: Contribution to journalArticleResearchpeer-review

139 Citations (Scopus)


Alzheimer's disease (AD)-pathology may play a role in Parkinson's disease (PD)-related dementia (PDD). The aim of this study was to assess cerebrospinal fluid (CSF) levels of tau, phospho-tau, and beta-amyloid, proposed AD biomarkers, and their relationship with cognitive function in PD. Forty PD patients [20 nondemented (PDND); 20 PDD] and 30 controls underwent CSF tau, phospho-tau, and beta-amyloid analysis using specific ELISA techniques. All PD patients and 15 controls underwent neuropsychological testing of fronto-subcortical (attention, fluency) and neocortical (memory, naming, visuoperceptive) functions. CSF markers levels were compared between groups, and compared and correlated with neuropsychological measures in PDND and PDD separately and as a continuum (PD). CSF tau and phospho-tau were higher in PDD than in PDND and controls (P < 0.05). CSF beta-amyloid ranged from high (controls) to intermediate (PDND) and low (PDD) levels (P < 0.001). In all PD and PDD patients, high CSF tau and phospho-tau were associated with impaired memory and naming. In PDND, CSF beta-amyloid was related with phonetic fluency. These findings suggest underlying AD-pathology in PDD in association with cortical cognitive dysfunction, and that low CSF beta-amyloid in PDND patients with impaired phonetic fluency can constitute an early marker of cognitive dysfunction.

Original languageAmerican English
Pages (from-to)2203-2210
Number of pages8
JournalMovement Disorders
Issue number15
Publication statusPublished - 15 Nov 2009


  • Beta-amyloid
  • Cerebrospinal fluid
  • Dementia
  • Neuropsychological function
  • Parkinson's disease
  • Tau


Dive into the research topics of 'Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease'. Together they form a unique fingerprint.

Cite this